Advanced search
Publication Cover
Immunopharmacology and Immunotoxicology Volume 37, 2015 - Issue 1
Submit an article Journal homepage
554
Views
14
CrossRef citations to date
0
Altmetric
Brief Communication

Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations

Daniele D'AmbrosioDepartment of Global Clinical Science & Epidemiology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland,
,
Jörg SteinmannInstitute of Immunology, University of Schleswig-Holstein, Kiel, Germany, and
,
Patrick BrossardDepartment of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
&
Jasper DingemanseDepartment of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandCorrespondence[email protected]
Pages 103-109 | Received 14 Jul 2014, Accepted 19 Nov 2014, Published online: 18 Dec 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Lluís Rusiñol, Elena Carmona-Rocha & Lluís Puig. (2023) Psoriasis: a focus on upcoming oral formulations. Expert Opinion on Investigational Drugs 32:7, pages 583-600.
Read now
Serena Ruggieri, Maria Esmeralda Quartuccio & Luca Prosperini. (2022) Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. Degenerative Neurological and Neuromuscular Disease 12, pages 61-73.
Read now
Elisa Baldin & Alessandra Lugaresi. (2020) Ponesimod for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 21:16, pages 1955-1964.
Read now
Stipo Jurcevic, Pierre-Eric Juif, Colleen Hamid, Roseanna Greenlaw, Daniele D’Ambrosio & Jasper Dingemanse. (2017) Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy 11, pages 123-131.
Read now
Pierre-Eric Juif, Stephan Kraehenbuehl & Jasper Dingemanse. (2016) Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opinion on Drug Metabolism & Toxicology 12:8, pages 879-895.
Read now

Articles from other publishers (9)

Mateusz Matwiejuk, Hanna Mysliwiec, Bartłomiej Lukaszuk, Marta Lewoc, Hend Malla, Piotr Mysliwiec, Jacek Dadan, Adrian Chabowski & Iwona Flisiak. (2023) The Interplay between Bioactive Sphingolipids in the Psoriatic Skin and the Severity of the Disease. International Journal of Molecular Sciences 24:14, pages 11336.
Crossref
Anthony T Reder, Olaf Stuve, Stephanie K Tankou & Thomas P Leist. (2022) T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Multiple Sclerosis Journal 29:6, pages 648-656.
Crossref
Yuechun Zhao, Yuheng Zhang, Jiaqi Li, Ningxin Zhang, Qiubai Jin, Yuxia Qi & Ping Song. (2023) Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target. Lipids in Health and Disease 22:1.
Crossref
Gary Álvarez Bravo, René Robles Cedeño, Marc Puig Casadevall & Lluís Ramió-Torrentà. (2022) Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Cells 11:13, pages 2058.
Crossref
Sarah HarrisJonathan Q. TranHarry SouthworthCollin M. SpencerBruce A.C. CreeScott S. Zamvil. (2020) Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurology Neuroimmunology & Neuroinflammation 7:5.
Crossref
Zuoquan Xie, Hong Liu & Meiyu Geng. (2017) Targeting sphingosine-1-phosphate signaling for cancer therapy. Science China Life Sciences 60:6, pages 585-600.
Crossref
Dominik Lott, Andreas Krause, Christian A. Seemayer, Daniel S. Strasser, Jasper Dingemanse & Thorsten Lehr. (2016) Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes. Pharmaceutical Research 34:3, pages 599-609.
Crossref
Zenas Z. N. Yiu & Richard B. Warren. (2016) Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology 17:3, pages 191-200.
Crossref
Daniele D’Ambrosio, Mark S. Freedman & Joerg Prinz. (2016) Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Therapeutic Advances in Chronic Disease 7:1, pages 18-33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.